Ponatinib potently inhibits activating variants of RET in models of thyroid cancer [13, 14], and others have shown that ponatinib inhibits KIF5B-RET fusions in genetically engineered models (but not patient-derived xenograft [PDX] models) [15]. The gene discussed is KIF5B; the disease is thyroid cancer.